


AMENDMENTS TO THE CLAIMS

Delete claims 2 and 3.

Please amend claims 1 and 7 as follows.

Claim 1 (amended once) A compound of Formula I, and pharmaceutically acceptable salts thereof,



Formula I

wherein:

R_1 is $-(CR^aR^b)_n-X$;

R^a , R^b are each independently selected from the group consisting of H, C_{1-6} alkyl; each of said C_{1-6} alkyl being optionally substituted with one to six same or different halogen;

X is H or C_{1-6} alkyl; said C_{1-6} alkyl being optionally substituted with a member selected from the group consisting of (1) one to six same or different halogen or hydroxy; (2) heteroaryl; (3) non-aromatic heterocyclic ring and (4) a member selected from Group A;

n is 1-6;

~~Group A is a member selected from the group consisting of halogen, CN, OR^x , $N^+R^eR^dR^e[F^-]$, NR^eR^d , COR^e , CO_2R^x , $CONR^xR^y$ and $S(O)_mR^e$;~~

~~R^x and R^y are independently H or C_{1-6} alkyl;~~

~~R^e , R^d and R^e are independently C_{1-6} alkyl;~~


~~m is 0-2~~


~~T is halogen, CF_3SO_3^- or CH_3SO_3^- ;~~

R₂ and R₅ are independently halogen or H;

R₃ and R₄ are each independently selected from the group consisting of H, halogen and C₁₋₆ alkyl; said C₁₋₆ alkyl can be optionally substituted with one to six same or different halogen;

Q is a member selected from the group consisting of





F_1 is CH or N;

R_6 is selected from the group consisting of H, halogen, NR^fR^g , SR^n and a five-membered heteroaryl containing one to two of the same or different heteroatoms selected from the group consisting of O, S and N;

R^f and R^g are independently H, C_{1-6} alkyl or C_{1-6} alkyl; said C_{1-6} alkyl optionally substituted with OR^h or CO_2R^h ;

R^h is and R^i are independently H or C_{1-6} alkyl;

R^n is C_{1-6} alkyl optionally substituted with CO_2R^h ;

R_7 is H, or CO_2R^h ;

R_8 is H, COR^h , CO_2R^h or C_{1-6} alkyl; said C_{1-6} alkyl optionally substituted with OR^h ;

R_9 is H, halogen, heteroaryl, phenyl, phenyl substituted with a halogen group, phenyl substituted with a methanesulfonyl group, COR^h , CO_2R^h , C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-4} alkynyl; said C_{2-4} alkynyl optionally substituted with C_{1-6} cycloalkyl;

~~R₁₀ and R₁₁ are independently H, NO₂ or NR^hRⁱ~~

~~R₁₂ is H, CO₂R^h or C₁₋₂-alkyl; said C₁₋₂-alkyl optionally substituted with phenyl;~~

~~R₁₃ and R₁₄ are independently selected from the group consisting of H, OR^h, CONRⁱR^k, NRⁱR^m and pyrrolidine; wherein said pyrrolidine is attached at the nitrogen atom;~~

~~Rⁱ and R^k are independently H or C₁₋₆-alkyl optionally substituted with phenyl;~~

~~Rⁱ and R^m are independently C₁₋₆-alkyl;~~

~~R₁₅ and R₁₆ are independently selected from the group consisting of H, OR^h, phenyl, pyridyl and C₁₋₆-alkyl; said C₁₋₆-alkyl optionally substituted with CO₂R^h;~~

~~R₁₇ and R₁₈ are independently selected from the group consisting of halogen, NRⁱR^m, SR^h and morpholine; wherein said morpholine is attached at the nitrogen atom;~~

~~R₁₉ is selected from the group consisting of H, phenyl, C₂₋₆-alkenyl and C₁₋₆-alkyl; said C₁₋₆-alkyl optionally substituted with one to six same or different halogen, CO₂R^h, CONR^hRⁱ, pyridyl and one to three phenyl groups; wherein in the case of C₁₋₆-alkyl substituted with one phenyl group, said phenyl group is optionally substituted with a member selected from the group consisting of halogen, PO(OR^h)₂, CO₂R^h, SO₂Rⁿ and CONR^hRⁱ;~~

~~Rⁿ is C₁₋₆-alkyl;~~

~~R₂₀ and R₂₁ are independently H or halogen;~~

~~R₂₂ is C₁₋₆-alkyl;~~

~~R₂₃ and R₂₄ are independently H or C₁₋₆-alkyl;~~

~~R₂₅ is C₁₋₆-cycloalkyl or C₁₋₆-alkyl; said C₁₋₆-alkyl group optionally substituted with a member selected from the group consisting of CO₂R^h, PhCO₂R^h and one to six same or different halogens;~~

R₂₆ is selected from the group consisting of H, halogen, C₁₋₆ alkyl; C₂₋₆ alkenyl, OR^h and COR^h; said C₂₋₆ alkenyl being optionally substituted with OR^h;

R₂₇ is H, OR^h or CO₂R^h;

R₂₈ is CO₂R^h; and

R₂₉ is H or halogen; and

~~heteroaryl is a 5- or 6-membered aromatic ring containing at least one and up to four non-carbon atoms selected from the group consisting of O, N and S;~~

~~non-aromatic heterocyclic ring is a 3 to 7-membered non-aromatic ring containing at least one and up to four non-carbon atoms selected from the group consisting of O, N and S; and~~

~~p is 0-2.~~

Claim 2 (cancelled).

Claim 3 (cancelled).

Claim 4 (original) A compound of claim 1 wherein:

R^a and R^b are hydrogen.

Claim 5 (original) A compound of claim 1 wherein:

R₁ is -(CH₂)_n-X and n is 2-4.


Claim 6 (original) A compound in claim 1 wherein R_3 and R_4 are each independently selected from the group consisting of H, fluorine and C_{1-2} alkyl; said C_{1-2} alkyl being optionally substituted with one to three fluorine atoms.

Claim 7 (amended once) A compound in claim 1 wherein:

R_1 is 3-methyl-2-butyl or $-(CH_2)_n-X$; and wherein n is 2-4.

~~X is a member selected from the group consisting of~~

~~$-F$, $-CN$, $-SR^c$, $-SO_2R^c$, $-OR^x$, $-COR^c$, CO_2R^x , $CONR^xR^y$,
 $[NR^cR^dR^e][T^-]$, $-$~~



R^e , R^d and R^e are independently C_{1-4} alkyl; and

R^x and R^y are independently H or C_{1-4} alkyl.

Claim 8 (original) A compound of claim 1 wherein:

R_2 and R_5 are independently H.

Claim 9 (previously cancelled).

Claim 10 (original) A pharmaceutical composition which comprises a therapeutically effective amount of one or more of the aforementioned compounds as claimed in any one of claims 1-8, and a pharmaceutically acceptable carrier.